In depth

A summary of the key trial publications on the use of PD-1 pathway and CTLA-4 inhibitors alone or in combination in the second-line or later treatment of locally advanced and metastatic urothelial carcinoma.

This independent article was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

This article summarizes the top-line results of the published trials of immunotherapeutic agents – used as monotherapy, in combination with chemotherapy, or as maintenance – in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

A quick guide to the JAVELIN clinical trials investigating the efficacy and safety of the PD-L1 inhibitor avelumab in the lung cancer setting.

Narjust Duma, from the University of Wisconsin, discusses the key issues regarding COVID-19 vaccination in people with cancer.

A quick-reference guide to the CheckMate trials investigating the anti-PD-1 agent nivolumab, as monotherapy or in combination with the anti-CTLA-4 agent ipilimumab, in patients with renal cell carcinoma.

Gary Lyman discusses the effects of the coronavirus pandemic on various aspects of oncology clinical trials, from accrual to analysis, and highlights the need for robust research on COVID-19 and cancer.

Co-project leader Lennard Lee talks about the inception and development of the initiative that will provide insight into the impact of COVID-19 on people with cancer and facilitate shared learning that will benefit patient care.

Gilberto Lopes, a steering committee member of CCC19, tells us about the registry collating data on cancer patients with comorbid COVID-19 to provide an evidence base for future decision-making.

Thoracic oncology nurse practitioner Beth Sandy explains how the coronavirus pandemic is affecting cancer patient care and how strategies such as telemedicine are coming into their own.

Genitourinary oncologists Cora Sternberg and Axel Merseburger share their experience of managing cancer patients during the COVID-19 pandemic, comparing perspectives from a US and German stand point.

Gilberto Lopes discusses the impact of the COVID-19 pandemic on the management of patients with lung cancer and outlines the measures being implemented to minimize the risk for patients.

Thomas Flaig discusses the NCCN patient-oriented guidelines for bladder cancer, with a view to explaining the need for the guidance and what patients can hope to get from it.

A quick-reference guide to the IMmotion trials evaluating the anti-PD-L1 agent atezolizumab for the treatment of renal cell carcinoma.

A quick-access guide to the JAVELIN trials of the anti-PD-L1 agent avelumab in the renal cell carcinoma setting.

A quick-reference guide to the KEYNOTE clinical trials evaluating the immune checkpoint inhibitor pembrolizumab in patients with renal cell carcinoma.

Here we round up the CheckMate trials evaluating the PD-1 inhibitor nivolumab in non-small-cell lung cancer and small-cell lung cancer.

A round-up of the key studies – all published in Science – that have investigated the association between the gut microbiome and response to immune checkpoint inhibitors.

In light of recent reports of hyperprogression in response to treatment with cancer immunotherapy, medwireNews spoke to medical oncologist Razelle Kurzrock (University of California, San Diego, La Jolla, USA) about the phenomenon, the implications for therapy, and future directions for research.